

HAEMONETICS®

Haemonetics 4th Quarter and Fiscal Year 2017 Earnings Release and Fiscal Year 2018 Guidance Available on Investor Relations Website

May 8, 2017

Financial release accessible online

BRAINTREE, Mass., May 8, 2017 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that fourth quarter and fiscal year 2017 financial results and fiscal 2018 guidance are available on its Investor relations website.

HAEMONETICS®

The Company is posting this press release and, additionally, results tables that will be referenced on its webcast to its Investor Relations website.

Direct link to **Earnings Release FY17 Q4:**

<https://haemonetics.gcs-web.com/static-files/4a7eb0eb-12d4-43cd-963d-8f76d88fe07c>

Direct link to **Results Tables That Will Be Referenced on the Webcast:**

<https://haemonetics.gcs-web.com/static-files/fd8345b3-9b6d-4257-88ed-4315d89ff4b3>

As previously announced, the Company will host a conference call with investors and analysts to discuss and answer questions about the results at 8:00am Eastern Time on May 8, 2017. A live webcast of the call can be accessed on Haemonetics' investor relations website.

Direct link to **Conference Call Webcast:** <http://edge.media-server.com/m/p/6zwag47r>.

About Haemonetics

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for our customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at <http://www.haemonetics.com>.

INVESTOR CONTACT:

Gerry Gould, VP-Investor Relations
(781) 356-9402
gerry.gould@haemonetics.com

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/haemonetics-4th-quarter-and-fiscal-year-2017-earnings-release-and-fiscal-year-2018-guidance-available-on-investor-relations-website-300452723.html>

SOURCE Haemonetics Corporation